贝伐单抗联合 XELOX 方案治疗转移性结直肠癌的研究进展

Advances in bevacizumab combined with XELOX regimen in the treament of metastatic colorectal cancer

结直肠癌（Colorectal cancer，CRC）是常见的消化系统恶性肿瘤，近几十年来其发病率和死亡率在全球范围内呈上升趋势。目前，在进展期结直肠癌的治疗中，化疗仍起重要作用，靶向治疗为患者带来新的希望，而且随着新一代化疗药物和靶向药物广泛应用于临床，患者生存质量得到了极大的改善，生存期得到了显著延长，靶向联合化疗也已成为转移性结直肠癌治疗研究热点之一。奥沙利铂＋卡培他滨（XELOX）作为一线化疗方案治疗转移性结直肠癌（mCRC）能取得很好的疗效，副作用轻，患者耐受良好；贝伐单抗作为一种新型靶向抗肿瘤药物，在抑制肿瘤组织生长和降低肿瘤细胞血行转移率方面显示出良好的效果。贝伐单抗联合XELOX方案治疗mCRC已被广泛研究报道，本文就对其疗效及安全性进行简要综述。

Colorectal cancer is a common malignant tumor in digestive system ,with an increasing inci-dence rate and case fatality rate all over the world in recent decades .At present,chemotherapy still plays a very important role in the treatment of advanced colorectal cancer .Targeted therapy brings new hope to patients ,and new chemotherapy drugs and targeted drugs have been widely used in clinics .Patient′s life quality has been great-ly improved,survival time has been significantly prolonged ,the combination of chemotherapy and targeted therapy has also become a hot research area in the treatment of metastatic colorectal cancer .XELOX （ capecitabine plus oxaliplatin）as a first-line chemotherapy regimen in treating metastatic colorectal cancer （mCRC）can obtain good therapeutic effect ,the side effects of XELOX are light and well tolerated;Bevacizumab ,as a new type of targeted anti-tumor drugs ,shows a good effect in inhibiting tumor growth and reducing its hematogenous spread risk .Bev-acizumab in combination with XELOX regimen for treating mCRC has been widely investigated and reported .This review gives a brief summary on the efficacy and safety of the combined administration of Bevacizumab and XE -LOX.